Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Lessons from PROMINENT and prospects for pemafibrate.

Cardiovascular diabetology·2024

Same author

Effect of Pemafibrate on Diabetic Foot Ulceration and Gangrene: An Exploratory Analysis From PROMINENT.

Journal of the American College of Cardiology·2024

Same author

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.

The New England journal of medicine·2022

Same author

Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis.

Cells·2022

Same author

Prospective associations between multiple lifestyle behaviors and depressive symptoms.

Journal of affective disorders·2022

Same author

Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel.

Frontiers in cardiovascular medicine·2022

Same journal

Editorial introduction.

Current opinion in lipidology·2026

Same journal

Heterozygosity for pathogenic variants in familial chylomicronemia syndrome genes: from carrier state to complex trait.

Current opinion in lipidology·2026

Same journal

Premature atherosclerotic cardiovascular disease in the MENA region: economic impact, barriers to care, and policy recommendations for an escalating crisis.

Current opinion in lipidology·2026

Same journal

The role of metabolic profiling and dietary intervention in the early diagnosis and prevention of atherosclerosis.

Current opinion in lipidology·2026

Same journal

A JAK of two trades: beneficial or adverse effects of Janus kinase inhibition for plasma LDL-cholesterol and major adverse cardiovascular events in inflammatory bowel disease patients?

Current opinion in lipidology·2026

Same journal

Inflammation and atherosclerotic cardiovascular disease: where do we go from here?

Current opinion in lipidology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 6, 2026

Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants

Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants

Published on: August 18, 2008

SPPARM alpha: the Lazarus effect.

Jean-Charles Fruchart¹, Raul D Santos^2,3

¹Ri Foundation, Basel, Switzerland.

Current Opinion in Lipidology

|October 3, 2019

Summary

This summary is machine-generated.

Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) show promise in managing atherogenic dyslipidaemia in type 2 diabetes mellitus (T2DM). Pemafibrate, a novel SPPARMα agonist, demonstrates efficacy and improved safety, with cardiovascular outcomes pending.

More Related Videos

Rat Model of the Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy ALPPS Procedure

Rat Model of the Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy ALPPS Procedure

Published on: August 14, 2017

Paw-Print Analysis of Contrast-Enhanced Recordings PrAnCER: A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits

Paw-Print Analysis of Contrast-Enhanced Recordings PrAnCER: A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits

Published on: August 12, 2019

Related Experiment Videos

Last Updated: Jan 6, 2026

Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants

Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants

Published on: August 18, 2008

Rat Model of the Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy ALPPS Procedure

Rat Model of the Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy ALPPS Procedure

Published on: August 14, 2017

Paw-Print Analysis of Contrast-Enhanced Recordings PrAnCER: A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits

Paw-Print Analysis of Contrast-Enhanced Recordings PrAnCER: A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits

Published on: August 12, 2019

Area of Science:

Cardiovascular Medicine
Endocrinology
Pharmacology

Background:

Atherogenic dyslipidaemia is common in type 2 diabetes mellitus (T2DM), increasing cardiovascular risk.
Fibrates manage hypertriglyceridaemia but have limitations including drug interactions and safety concerns.
Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offer a potential improvement over traditional fibrates.

Purpose of the Study:

To review the evidence for pemafibrate, a novel SPPARMα agonist.
To evaluate its efficacy in lipid management and non-lipid benefits.
To assess its safety and tolerability profile in patients with T2DM.

Main Methods:

Review of clinical trial data for pemafibrate.
Analysis of lipid profiles, including triglycerides and HDL-C.
Assessment of safety data, including renal and hepatic parameters.

Main Results:

Pemafibrate effectively lowers triglyceride-rich lipoproteins and raises HDL-C.
It exhibits beneficial non-lipid effects, such as anti-inflammatory activity.
Pemafibrate demonstrates a favourable safety profile with improved renal and hepatic safety compared to fenofibrate.

Conclusions:

SPPARMα represents a new therapeutic approach for reducing residual cardiovascular risk in T2DM.
Pemafibrate shows potential as a distinct therapeutic class.
The PROMINENT trial is crucial for validating pemafibrate's cardiovascular benefits and long-term safety.